ALX Oncology
866 Malcolm Road, Suite 100
Burlingame
CA
94010
United States
Tel: 650-466-7125
Website: http://www.alexotherapeutics.com/
Email: hr@alxoncology.com
60 articles with ALX Oncology
-
ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies
6/14/2021
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced updates on its ALX148 Phase 2 studies in patients with advanced head and neck squamous cell carcinoma.
-
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
-
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer
6/10/2021
ALX Oncology announced it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company to evaluate the combination of ALX148, a next generation CD47 blocker, and CYRAMZA®, Lilly’s anti-VEGFR2 antibody, for the treatment of patients with HER2-positive gastric cancer or gastroesophageal junction cancer.
-
venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.
-
ALX Oncology Announces Upcoming Virtual Investor Conference Participation
5/18/2021
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences.
-
ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
5/17/2021
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31, 2021 and provided recent clinical development and operational highlights.
-
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
5/10/2021
ALX Oncology Holdings Inc. in partnership with Merck, known as MSD outside the United States and Canada, announced the first patient has been dosed in the Phase 2 ASPEN-03 study evaluating the combination of ALX148, a next generation CD47 blocker, with KEYTRUDA®, Merck’s anti-PD-1 therapy, for the treatment of patients with advanced head and neck squamous cell carcinoma.
-
ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer
4/21/2021
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that our Phase 1b study of ALX148 in patients with advanced gastric or gastroesophageal junction cancer has been selected for a short oral presentation at the ESMO 23 rd World Congress on Gastrointestinal Cancer to be held virtually from June 30 – July 3, 2021.
-
ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148
4/5/2021
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announces that the post-grant review period for granted U.S. Patent No. 10,696,730 ended on March 30, 2021.
-
ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
3/18/2021
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided clinical development and operational highlights.
-
ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors
3/15/2021
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Sophia Randolph, M.D., Ph.D., to its Board of Directors.
-
ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics
3/4/2021
Companies will combine their unique scientific and technical expertise to develop a first-in-class anti-SIRPα antibody conjugated to TLR9 agonist (“SIRPα TRAAC”) that delivers targeted immune activation
-
ALX Oncology to Participate at H.C. Wainwright Global Life Sciences Conference
3/2/2021
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in a fireside chat at H.C. Wainwright’s Global Life Sciences Conference, being held virtually on March 9-10, 2021.
-
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021
1/11/2021
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, provided a corporate update and highlighted key milestones anticipated in 2021.
-
ALX Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference
1/5/2021
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 at 10:50 am ET.
-
ALX Oncology Added to the NASDAQ Biotechnology Index
12/17/2020
ALX Oncology Holdings Inc., (“ALX Oncology”) (NASDAQ: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that it has been selected for addition to the NASDAQ Biotechnology Index ® (NASDAQ: NBI). ALX’s addition to the NBI will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a s
-
ALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
12/14/2020
ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the closing of its previously announced underwritten public offering of 2,737,000 shares of its common stock,
-
ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock - Dec 10, 2020
12/10/2020
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, announced the pricing of an upsized underwritten public offering of 2,380,000 shares of its common stock at a price of $76.00 per share.
-
Due to the registration potential of the mid-stage studies, the U.S. Food and Drug Administration requested the company complete a standard safety study, which amounts to a partial clinical hold on the study.
-
ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies
12/7/2020
Due to the registration potential of two planned Phase 2 head and neck cancer studies, FDA has requested completion of a standard ongoing non-clinical safety study